Skip to Main Content

Paper Details

AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Cancer Discov
36
2022
-, AXL, DNA polymerases, DTP, EGFR, EGFR mutation, EGFR-Mutant Lung Cancer, EGFR-mutant lung cancers, EGFRi, GAS6, MYC, RAD18, drug, drug-tolerant persister (DTP) cells, drug-treated cells, endogenous, hypermutators, lung cancer, patient, patients, purine, pyrimidines, resistant cells, treated cells, tumors, xenograft models
Author NameAffiliation
Collin M BlakelyUniversity of California san francisco
Collin M BlakelyHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Stefan WiemannGerman Cancer Research Center (DKFZ)
Trever G BivonaUniversity of California san francisco
Trever G BivonaHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Trever G BivonaUniversity of California san francisco
Joan S BruggeHarvard Medical School
Aviv RegevGenentech Inc.
Aviv RegevGenentech Inc.
Gad GetzBroad Institute of MIT and Harvard
Gad GetzCancer Center and Department of Pathology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Gad GetzBroad Institute of MIT and Harvard
Gad GetzCancer Center and Department of Pathology, Massachusetts General Hospital Cancer Center, Harvard Medical School
Eytan Ruppin
  • 1 - 14

Datasets

Release 1.2